MX2009006082A - Anticuerpos monoclonales contra la proteina 3 similar a angiopoyetina (angptl3). - Google Patents
Anticuerpos monoclonales contra la proteina 3 similar a angiopoyetina (angptl3).Info
- Publication number
- MX2009006082A MX2009006082A MX2009006082A MX2009006082A MX2009006082A MX 2009006082 A MX2009006082 A MX 2009006082A MX 2009006082 A MX2009006082 A MX 2009006082A MX 2009006082 A MX2009006082 A MX 2009006082A MX 2009006082 A MX2009006082 A MX 2009006082A
- Authority
- MX
- Mexico
- Prior art keywords
- monoclonal antibodies
- antibodies against
- angptl3
- against angptl3
- neutralize
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Se proporcionan anticuerpos monoclonales que se enlazan específicamente a la ANGPTL3. Se proporcionan anticuerpos monoclonales que neutralizan al menos, una actividad de ANGPTL3. Se proporcionan métodos para tratar un trastorno de metabolismo lípido usando anticuerpos monoclonales neutralizantes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87383406P | 2006-12-08 | 2006-12-08 | |
PCT/US2007/025080 WO2008073300A2 (en) | 2006-12-08 | 2007-12-06 | Monoclonal antibodies against angptl3 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009006082A true MX2009006082A (es) | 2009-08-18 |
Family
ID=39512267
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009006082A MX2009006082A (es) | 2006-12-08 | 2007-12-06 | Anticuerpos monoclonales contra la proteina 3 similar a angiopoyetina (angptl3). |
Country Status (21)
Country | Link |
---|---|
US (2) | US7935796B2 (es) |
EP (1) | EP2121751B1 (es) |
JP (1) | JP5484063B2 (es) |
KR (1) | KR101503937B1 (es) |
CN (1) | CN101855241B (es) |
AR (1) | AR064205A1 (es) |
AU (1) | AU2007332855B2 (es) |
BR (1) | BRPI0720218A2 (es) |
CA (1) | CA2672049C (es) |
DK (1) | DK2121751T3 (es) |
EA (1) | EA019661B1 (es) |
ES (1) | ES2618830T3 (es) |
HU (1) | HUE033960T2 (es) |
IL (1) | IL199216A (es) |
MX (1) | MX2009006082A (es) |
NO (1) | NO20092215L (es) |
PL (1) | PL2121751T3 (es) |
PT (1) | PT2121751T (es) |
TW (1) | TW200846364A (es) |
WO (1) | WO2008073300A2 (es) |
ZA (1) | ZA200904022B (es) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE033960T2 (en) * | 2006-12-08 | 2018-01-29 | Lexicon Pharmaceuticals Inc | Monoclonal Antibodies to ANGPTL3 |
WO2010042292A1 (en) * | 2008-10-08 | 2010-04-15 | Trustees Of Dartmouth College | Method for selectively inhibiting the activity of acat1 in the treatment of alzheimer's disease |
US9149492B2 (en) | 2008-10-08 | 2015-10-06 | Trustees Of Dartmouth College | Method for selectively inhibiting ACAT1 in the treatment of alzheimer's disease |
US8802646B2 (en) | 2008-10-08 | 2014-08-12 | Trustees Of Dartmouth College | Method for selectively inhibiting the activity of ACAT1 in the treatment of alzheimer's disease |
US9388413B2 (en) | 2008-10-08 | 2016-07-12 | Trustees Of Dartmouth College | Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases |
US9388414B2 (en) | 2008-10-08 | 2016-07-12 | Trustees Of Dartmouth College | Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases |
US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
CN101852805B (zh) * | 2009-03-31 | 2015-04-01 | 浙江大学 | Angptl3作为卵巢癌的诊断标记物的用途 |
JP5822845B2 (ja) * | 2010-01-08 | 2015-11-25 | アイシス ファーマシューティカルズ, インコーポレーテッド | アンジオポエチン様3発現の調節 |
AU2015200969A1 (en) * | 2010-01-08 | 2015-03-19 | Ionis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
NZ701539A (en) | 2010-03-04 | 2015-04-24 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
US8802091B2 (en) | 2010-03-04 | 2014-08-12 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
US9592331B2 (en) | 2011-02-07 | 2017-03-14 | Aggamin Llc | Methods and systems for treating eclampsia or pre-eclampsia |
WO2012154983A2 (en) | 2011-05-10 | 2012-11-15 | Biocare Medical, Llc | Systems and methods for anti-pax8 antibodies |
AR087329A1 (es) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
CN112961855A (zh) * | 2011-06-21 | 2021-06-15 | 阿尔尼拉姆医药品有限公司 | 血管生成素样3(ANGPTL3)iRNA组合物及其使用方法 |
BR112013032145B1 (pt) | 2011-06-23 | 2022-09-20 | Ablynx N.V | Técnicas para prever, detectar e reduzir interferência de proteína não especifica em ensaios envolvendo domínios variáveis únicos de imunoglobulina |
ES2773111T3 (es) | 2011-09-16 | 2020-07-09 | Regeneron Pharma | Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a) |
US10316103B1 (en) | 2012-03-30 | 2019-06-11 | Biocare Medical, Llc | Systems and methods for anti-Uroplakin III antibodies |
HRP20211641T1 (hr) | 2012-07-13 | 2022-02-04 | Roche Glycart Ag | Bispecifična protutijela anti-vegf/anti-ang-2 i njihova primjena u liječenju vaskularnih očnih bolesti |
CN104540852B (zh) | 2012-08-13 | 2018-10-02 | 瑞泽恩制药公司 | 具有pH-依赖性结合特性的抗-PCSK9抗体 |
ES2682345T3 (es) | 2012-09-27 | 2018-09-20 | Biocare Medical, Llc | Sistemas y procedimientos de anticuerpos antiuroplaquina II |
GB201219487D0 (en) * | 2012-10-30 | 2012-12-12 | Cancer Rec Tech Ltd | Anti-S100A4 antibody molecules and their uses |
US10429390B2 (en) | 2012-12-18 | 2019-10-01 | Biocare Medical, Llc | Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer |
JP6445467B2 (ja) | 2013-02-28 | 2019-01-09 | バイオケア メディカル, エルエルシー | 抗p40抗体システムおよび方法 |
US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
US9301971B2 (en) | 2013-03-08 | 2016-04-05 | Novartis Ag | Peptides and compositions for treatment of joint damage |
UY35368A (es) | 2013-03-08 | 2014-10-31 | Irm Llc | Péptidos y composiciones para el tratamiento de daño articular |
PT2992098T (pt) | 2013-05-01 | 2019-07-05 | Ionis Pharmaceuticals Inc | Composições e métodos para modular a expressão de hbv e ttr |
US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
DK3052522T3 (da) | 2013-10-03 | 2020-02-24 | Biocare Medical Llc | Anti-sox 10 antistofsystemer og -fremgangsmåder |
ES2754209T3 (es) | 2013-12-13 | 2020-04-16 | Stora Enso Oyj | Cartón multicapa |
PT3087183T (pt) * | 2013-12-24 | 2020-10-08 | Ionis Pharmaceuticals Inc | Modulação da expressão da proteína relacionada com angiopoietina 3 |
SI3137605T1 (sl) | 2014-05-01 | 2021-02-26 | Ionis Pharmaceuticals, Inc. | Sestavki in metode za modulacijo ekspresije angiopoetin 3-podobnega |
WO2015184105A1 (en) | 2014-05-29 | 2015-12-03 | Trustees Of Dartmouth College | Method for selectively inhibiting acat1 in the treatment of neurodegenerative diseases |
US9527922B2 (en) * | 2014-12-31 | 2016-12-27 | Development Center For Biotechnology | Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy |
AU2016247922B2 (en) | 2015-04-13 | 2022-04-28 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof |
AU2016349625B2 (en) | 2015-11-06 | 2022-07-07 | Ionis Pharmaceuticals, Inc. | Modulating apolipoprotein (a) expression |
DK3416684T3 (da) * | 2016-02-17 | 2023-07-31 | Regeneron Pharma | Fremgangsmåder til behandling eller forebyggelse af atherosklerose ved administration af en hæmmer af ANGPTL3 |
PE20190353A1 (es) | 2016-04-15 | 2019-03-07 | Macrogenics Inc | Moleculas de union b7-h3 novedosas, conjugados anticuerpo-farmaco de los mismos y metodos de uso de los mismos |
US20170312359A1 (en) * | 2016-04-28 | 2017-11-02 | Regeneron Pharmaceuticals, Inc. | Methods for treating patients with familial hypercholesterolemia |
EP3532034A4 (en) * | 2016-10-28 | 2020-12-02 | Washington University | ANTI-APOE ANTIBODIES |
CN107085112B (zh) * | 2017-05-10 | 2019-03-19 | 武汉圣润生物科技有限公司 | 一种用于检测白血病的试剂盒 |
WO2019195561A2 (en) * | 2018-04-06 | 2019-10-10 | BioLegend, Inc. | Anti-tetraspanin 33 agents and compositions and methods for making and using the same |
AU2019312692A1 (en) | 2018-08-02 | 2021-03-11 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
TW202027794A (zh) | 2018-10-03 | 2020-08-01 | 瑞士商諾華公司 | 血管生成素樣3多肽之持續遞送 |
TWI747098B (zh) | 2018-12-21 | 2021-11-21 | 美商美國禮來大藥廠 | 抗angptl3/8複合物抗體及其使用方法 |
US20200369760A1 (en) | 2019-05-24 | 2020-11-26 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-angptl3 antibodies |
CN112062845B (zh) * | 2019-06-10 | 2022-09-02 | 山东博安生物技术股份有限公司 | Angptl3结合片段及其用途 |
MX2022000094A (es) * | 2019-07-04 | 2022-04-27 | Cadila Healthcare Ltd | Vacuna a base de angptl3 para el tratamiento de enfermedad hepática. |
WO2021041300A2 (en) * | 2019-08-23 | 2021-03-04 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
CN110938144B (zh) * | 2019-11-27 | 2022-07-26 | 复旦大学附属儿科医院 | 一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途 |
CA3166346A1 (en) * | 2020-01-22 | 2021-07-29 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-angptl3 antibody and use thereof |
WO2022109443A1 (en) * | 2020-11-23 | 2022-05-27 | The Regents Of The University Of Michigan | Single-chain antibody against flavivirus ns1 protein |
WO2022187435A1 (en) | 2021-03-04 | 2022-09-09 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
WO2022187353A1 (en) * | 2021-03-05 | 2022-09-09 | Anji Pharmaceuticals Inc. | Methods and compositions for treating sepsis |
JPWO2022244845A1 (es) * | 2021-05-19 | 2022-11-24 | ||
WO2023283613A1 (en) * | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
IL309912A (en) * | 2021-07-09 | 2024-03-01 | Dyne Therapeutics Inc | Muscle targeting complexes and their uses for the treatment of dystrophinopathy |
US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
KR20240035835A (ko) * | 2021-07-21 | 2024-03-18 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 항-angptl3 항체 또는 이의 항원 결합 단편의 약학적 조성물 및 이의 응용 |
CN116284377A (zh) * | 2021-12-21 | 2023-06-23 | 复旦大学 | 抗人血管生成素3纳米抗体及其应用 |
US11780910B1 (en) | 2022-05-02 | 2023-10-10 | Novo Nordisk A/S | Anti-ANGPTL3 antibodies suitable for high concentration compositions and subcutaneous administration |
CN117447595B (zh) * | 2022-07-26 | 2024-06-28 | 北京东方百泰生物科技股份有限公司 | 一种抗Siglec-15单克隆抗体 |
CN116199779B (zh) * | 2022-12-08 | 2023-08-11 | 北京东方百泰生物科技股份有限公司 | 一种抗lilrb4单克隆抗体、其抗原结合片段及其应用 |
WO2024130165A1 (en) | 2022-12-16 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
JP3693671B2 (ja) | 1991-03-15 | 2005-09-07 | アムゲン インコーポレーテッド | ポリペプチドのpeg化 |
US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
JP4157160B2 (ja) | 1991-12-13 | 2008-09-24 | ゾーマ テクノロジー リミテッド | 改変抗体可変領域の調製のための方法 |
US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
US5912000A (en) | 1994-09-23 | 1999-06-15 | Zonagen, Inc. | Chitosan induced immunopotentiation |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
TW313568B (es) | 1994-12-20 | 1997-08-21 | Hoffmann La Roche | |
US6127977A (en) | 1996-11-08 | 2000-10-03 | Cohen; Nathan | Microstrip patch antenna with fractal structure |
EP2314625B1 (en) | 1996-12-03 | 2014-05-07 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
US20030100051A1 (en) * | 1998-05-12 | 2003-05-29 | Ruben Steven M. | 97 human secreted proteins |
US5980912A (en) | 1997-03-25 | 1999-11-09 | Zonagen, Inc. | Chitosan induced immunopotentiation |
US6030831A (en) * | 1997-09-19 | 2000-02-29 | Genetech, Inc. | Tie ligand homologues |
WO1999067382A2 (en) * | 1998-06-24 | 1999-12-29 | Compugen Ltd. | Angiopoietin-like growth factor sequences |
RU2002115295A (ru) | 1999-12-09 | 2004-01-10 | Санкио Компани, Лимитед (Jp) | Способ испытания терапевтического или профилактического средства от гиперлипидемии |
EP1403367A4 (en) | 2001-06-08 | 2005-08-17 | Sankyo Co | A MEDICAMENT TEST METHOD FOR TREATING OR PREVENTING DISEASES SUCH AS HYPERLIPEMIA |
CN101905024A (zh) | 2001-11-16 | 2010-12-08 | 杰南技术公司 | 含有血管生成素-样蛋白质3angptl3的组合物及其使用方法 |
AU2006204001B2 (en) | 2005-01-07 | 2011-06-16 | Lexicon Pharmaceuticals, Inc. | Monoclonal antibodies against angiopoietin-like protein 4 (ANGPTL4 ) |
HUE033960T2 (en) * | 2006-12-08 | 2018-01-29 | Lexicon Pharmaceuticals Inc | Monoclonal Antibodies to ANGPTL3 |
-
2007
- 2007-12-06 HU HUE07862629A patent/HUE033960T2/en unknown
- 2007-12-06 WO PCT/US2007/025080 patent/WO2008073300A2/en active Application Filing
- 2007-12-06 BR BRPI0720218-0A2A patent/BRPI0720218A2/pt not_active Application Discontinuation
- 2007-12-06 JP JP2009540313A patent/JP5484063B2/ja active Active
- 2007-12-06 US US12/001,012 patent/US7935796B2/en active Active
- 2007-12-06 KR KR1020097013595A patent/KR101503937B1/ko active IP Right Grant
- 2007-12-06 PT PT78626298T patent/PT2121751T/pt unknown
- 2007-12-06 EP EP07862629.8A patent/EP2121751B1/en active Active
- 2007-12-06 EA EA200970556A patent/EA019661B1/ru not_active IP Right Cessation
- 2007-12-06 ZA ZA200904022A patent/ZA200904022B/xx unknown
- 2007-12-06 AU AU2007332855A patent/AU2007332855B2/en not_active Ceased
- 2007-12-06 DK DK07862629.8T patent/DK2121751T3/en active
- 2007-12-06 ES ES07862629.8T patent/ES2618830T3/es active Active
- 2007-12-06 CA CA2672049A patent/CA2672049C/en active Active
- 2007-12-06 MX MX2009006082A patent/MX2009006082A/es active IP Right Grant
- 2007-12-06 PL PL07862629T patent/PL2121751T3/pl unknown
- 2007-12-06 CN CN2007800511058A patent/CN101855241B/zh active Active
- 2007-12-07 TW TW096146844A patent/TW200846364A/zh unknown
- 2007-12-07 AR ARP070105505A patent/AR064205A1/es active IP Right Grant
-
2009
- 2009-06-07 IL IL199216A patent/IL199216A/en active IP Right Grant
- 2009-06-09 NO NO20092215A patent/NO20092215L/no not_active Application Discontinuation
-
2011
- 2011-03-28 US US13/073,617 patent/US8742075B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EA200970556A1 (ru) | 2010-04-30 |
NO20092215L (no) | 2009-08-19 |
PL2121751T3 (pl) | 2017-07-31 |
CN101855241A (zh) | 2010-10-06 |
CA2672049C (en) | 2016-05-10 |
CN101855241B (zh) | 2013-11-06 |
WO2008073300A3 (en) | 2009-12-23 |
KR20090088925A (ko) | 2009-08-20 |
DK2121751T3 (en) | 2017-04-24 |
US8742075B2 (en) | 2014-06-03 |
JP2010512320A (ja) | 2010-04-22 |
US20080177045A1 (en) | 2008-07-24 |
PT2121751T (pt) | 2017-04-18 |
AU2007332855B2 (en) | 2012-08-16 |
JP5484063B2 (ja) | 2014-05-07 |
EP2121751B1 (en) | 2017-01-25 |
US20110243948A1 (en) | 2011-10-06 |
BRPI0720218A2 (pt) | 2013-12-24 |
EA019661B1 (ru) | 2014-05-30 |
IL199216A (en) | 2016-02-29 |
US7935796B2 (en) | 2011-05-03 |
ZA200904022B (en) | 2010-08-25 |
AR064205A1 (es) | 2009-03-18 |
EP2121751A2 (en) | 2009-11-25 |
AU2007332855A1 (en) | 2008-06-19 |
WO2008073300A2 (en) | 2008-06-19 |
CA2672049A1 (en) | 2008-06-19 |
EP2121751A4 (en) | 2012-01-11 |
ES2618830T3 (es) | 2017-06-22 |
HUE033960T2 (en) | 2018-01-29 |
KR101503937B1 (ko) | 2015-03-18 |
TW200846364A (en) | 2008-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009006082A (es) | Anticuerpos monoclonales contra la proteina 3 similar a angiopoyetina (angptl3). | |
MX2007008256A (es) | Anticuerpos monoclonales contra proteina 4 similar a angiopoyetina (angptl4). | |
HK1253579A1 (zh) | 用於治療癌症的單克隆抗體 | |
HK1209653A1 (en) | Monoclonal antibodies for tumor treatment | |
BRPI0811907A2 (pt) | Anticorpos monoclonais contra claudina-18 para tratamento de câncer. | |
HUS1600044I1 (hu) | Eljárások mielóma multiplex kezelésére, anti-CS1 ellenanyagokon alapuló terápiák kombinációjának alkalmazásával | |
IL197914A (en) | Antibodies to ereg for cancer treatment | |
HRP20180485T1 (hr) | Monoklonska antitijela za gt468 za liječenje raka | |
EP2134749A4 (en) | THERAPEUTIC MONOCLONAL ANTIBODIES FOR THE NEUTRALIZATION OF BOTULINE NEUROTOXINES | |
ZA201007751B (en) | Novel antibodies used to treat cancer | |
EP2414392A4 (en) | HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDES VCAM-1 AND COMPOSITION FOR TREATING INFLAMMATORY DISEASE OR CANCER COMPRISING THE SAME | |
HK1157798A1 (zh) | 使用結合 的人源化抗體的癌症治療 | |
EP2186894A4 (en) | MONOCLONAL ANTIBODY HAVING NEUTRALIZING ACTIVITY AGAINST MMP13 | |
IL207478A0 (en) | Monoclonal antibodies for tumor treatment | |
IL210247A0 (en) | Ccl20 - specific antibodies for cancer therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HH | Correction or change in general | ||
FG | Grant or registration |